Clinician-Selected FSH Starting Dose and Mature Oocyte Yield in Predicted Poor Responders (OPTIMAL-DOSE)
Association of Clinician-Selected FSH Starting Dose With Mature Oocyte Yield in Women With Predicted Poor Ovarian Response: The OPTIMAL-DOSE Prospective Cohort Study
This is a single-centre, prospective, non-interventional (observational) cohort study examining the association between the clinician-selected starting dose of follicle-stimulating hormone (FSH) and the yield of mature metaphase II (MII) oocytes in women with predicted poor ovarian response (Patient-Oriented Strategies Encompassing IndividualizeD Oocyte Number [POSEIDON] group 3 or 4) undergoing in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) with a gonadotropin-releasing hormone (GnRH) antagonist protocol. The FSH dose is chosen by the treating physician as part of routine care; the study does not allocate, randomize, or change treatment. The primary outcome is the number of MII oocytes per initiated index cycle. Because dosing is not randomized, analyses are adjusted for measured confounders and address confounding by indication.
Przegląd badań
Status
Status
Warunki
Warunki
Interwencja / Leczenie
Interwencja / Leczenie
Szczegółowy opis
Randomized evidence in predicted poor responders (a randomized trial in predicted poor responders and the 2024 Cochrane review of individualised gonadotropin dosing) does not show improved live birth from higher follicle-stimulating hormone (FSH) dosing, so this cohort is not designed to establish comparative efficacy; its contribution is a description of real-world dose-response patterns and local gonadotropin use and cost. Consecutive eligible women are enrolled after informed consent for data use, each contributing one index cycle. The exposure is the clinician-selected starting FSH dose, analysed as a continuous variable (per 75 international units [IU]), with categories of 150 IU or less versus more than 150 IU reported descriptively and in sensitivity analyses. The primary analysis is an adjusted negative-binomial regression of the metaphase II (MII) oocyte count on exposure, with adjusted means obtained by marginal standardization and an overlap-weighted propensity analysis as sensitivity. Reporting follows the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) and REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statements.
Typ studiów
Typ studiów
Zapisy (Szacowany)
Zapisy
Kontakty i lokalizacje
Kontakt w sprawie studiów
Kontakt w sprawie studiów
- Nazwa: Goksu Goc, MD
- Numer telefonu: +383 49 878 550
- E-mail: goksu.goc@gmail.com
Lokalizacje studiów
-
-
-
Pristina, Kosowo, 10000
- American Hospital Kosova
-
Kontakt:
- Goksu Goc, MD
- Numer telefonu: +383 49 878 550
- E-mail: goksu.goc@gmail.com
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Metoda próbkowania
Badana populacja
Consecutive women aged 18 to 42 years with predicted poor ovarian response (Patient-Oriented Strategies Encompassing IndividualizeD Oocyte Number (POSEIDON) group 3 or 4: anti-Mullerian hormone below 1.2 ng/mL and/or antral follicle count below 5) undergoing a gonadotropin-releasing hormone (GnRH) antagonist in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) cycle as part of routine clinical care at American Hospital Kosova, each contributing one index cycle.
Opis
Inclusion Criteria:
- Woman aged 18 to 42 years.
- Predicted poor ovarian response, Patient-Oriented Strategies Encompassing IndividualizeD Oocyte Number (POSEIDON) group 3 (under 35 years) or group 4 (35 years or older): anti-Mullerian hormone (AMH) below 1.2 ng/mL and/or antral follicle count (AFC) below 5 (both ovaries combined).
- Planned gonadotropin-releasing hormone (GnRH) antagonist in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) cycle as part of routine clinical care.
- First eligible (index) cycle during the study period; both ovaries present.
- Written informed consent for data collection and processing.
Exclusion Criteria:
- Predicted normal or high ovarian reserve (AMH 1.2 ng/mL or higher and AFC 5 or higher).
- Non-antagonist protocol (for example, long GnRH-agonist).
- Oocyte-donation or fertility-preservation (egg-freezing) cycle.
- A prior cycle of the same woman already enrolled in the study.
- Inability to provide informed consent.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Modele obserwacyjne: COHORT
- Perspektywy czasowe: PROSPECTIVE
Liczba grup / kohort
Kohorty i interwencje
Grupa / KohortaGrupa / Kohorta |
Interwencja / LeczenieInterwencja / Leczenie |
|---|---|
|
Lower starting dose (150 international units [IU] or less)
Women whose treating physician chose a starting daily follicle-stimulating hormone (FSH) dose of 150 international units (IU) or less as part of routine clinical care (observed, not assigned by the study). |
FSH administered per routine clinical practice; the starting dose is selected by the treating physician (observed exposure, not assigned by the study). Starting dose is analysed continuously (per 75 IU), with categories of 150 IU or less versus more than 150 IU reported descriptively. |
|
Higher starting dose (more than 150 IU)
Women whose treating physician chose a starting daily FSH dose of more than 150 IU (typically 225 IU) as part of routine clinical care (observed, not assigned by the study). |
FSH administered per routine clinical practice; the starting dose is selected by the treating physician (observed exposure, not assigned by the study). Starting dose is analysed continuously (per 75 IU), with categories of 150 IU or less versus more than 150 IU reported descriptively. |
Co mierzy badanie?
Podstawowe miary wyniku
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Number of mature metaphase II (MII) oocytes retrieved
Ramy czasowe: On the day of oocyte retrieval (up to 21 days after the start of ovarian stimulation)
|
Number of metaphase II (MII) oocytes retrieved per initiated index ovarian stimulation cycle, assessed by the embryologist at a standardized time after oocyte retrieval. Compared across the clinician-selected starting-dose exposure using adjusted analysis (associations, not causal effects). Cycles cancelled before oocyte retrieval contribute zero MII oocytes in the initiated-cycle analysis. Oocytes matured in vitro are excluded from the primary count. |
On the day of oocyte retrieval (up to 21 days after the start of ovarian stimulation)
|
Miary wyników drugorzędnych
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Total follicle-stimulating hormone (FSH) activity administered
Ramy czasowe: From the first to the last day of ovarian stimulation (up to 21 days)
|
Total follicle-stimulating hormone (FSH) activity administered during the index stimulation cycle, in international units (IU), by observed starting-dose exposure. FSH activity is recorded separately from luteinizing hormone (LH) and human chorionic gonadotropin (hCG) activity. |
From the first to the last day of ovarian stimulation (up to 21 days)
|
|
Gonadotropin medication cost
Ramy czasowe: From the first to the last day of ovarian stimulation (up to 21 days)
|
Cost of the gonadotropin medication used during the stimulation cycle, in euros (EUR), calculated using a pre-specified standardized unit-price table, by observed starting-dose exposure. |
From the first to the last day of ovarian stimulation (up to 21 days)
|
|
Total number of oocytes retrieved
Ramy czasowe: On the day of oocyte retrieval (up to 21 days after the start of ovarian stimulation)
|
Total number of oocytes retrieved at oocyte pick-up per initiated index cycle, by observed starting-dose exposure. |
On the day of oocyte retrieval (up to 21 days after the start of ovarian stimulation)
|
|
Oocyte maturity rate
Ramy czasowe: On the day of oocyte retrieval (up to 21 days after the start of ovarian stimulation)
|
Ratio of the number of metaphase II (MII) oocytes to the total number of oocytes retrieved in the index cycle, by observed starting-dose exposure. |
On the day of oocyte retrieval (up to 21 days after the start of ovarian stimulation)
|
|
Cycle cancellation before oocyte retrieval
Ramy czasowe: From the first day of ovarian stimulation to the planned day of oocyte retrieval (up to 21 days)
|
Whether the initiated index cycle was cancelled before oocyte retrieval, by observed starting-dose exposure. |
From the first day of ovarian stimulation to the planned day of oocyte retrieval (up to 21 days)
|
|
Duration of ovarian stimulation
Ramy czasowe: From the first to the last day of ovarian stimulation (up to 21 days)
|
Number of days of ovarian stimulation during the index cycle, by observed starting-dose exposure. |
From the first to the last day of ovarian stimulation (up to 21 days)
|
|
Number of normally fertilised oocytes with two pronuclei (2PN)
Ramy czasowe: At the fertilisation check, 1 day after oocyte retrieval (up to 22 days after the start of ovarian stimulation)
|
Number of oocytes showing two pronuclei (2PN) at the fertilisation check in the index cycle, by observed starting-dose exposure. |
At the fertilisation check, 1 day after oocyte retrieval (up to 22 days after the start of ovarian stimulation)
|
|
Number of usable embryos
Ramy czasowe: Up to 6 days after oocyte retrieval (up to 27 days after the start of ovarian stimulation)
|
Number of embryos from the index cycle that are transferred, cryopreserved or biopsied, meeting the minimum grade of the pre-specified laboratory standard, by observed starting-dose exposure. Each embryo is counted once. |
Up to 6 days after oocyte retrieval (up to 27 days after the start of ovarian stimulation)
|
|
Number of blastocysts
Ramy czasowe: Up to 6 days after oocyte retrieval (up to 27 days after the start of ovarian stimulation)
|
Number of embryos from the index cycle reaching the blastocyst stage, by observed starting-dose exposure. |
Up to 6 days after oocyte retrieval (up to 27 days after the start of ovarian stimulation)
|
Inne miary wyników
Inne miary wyników
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Live birth (exploratory)
Ramy czasowe: Up to 12 months after the start of ovarian stimulation
|
Delivery of at least one live-born infant, recorded per initiated index cycle and per transfer. Exploratory only; the study is not powered for this outcome and it is highly susceptible to confounding by indication. Reported descriptively. |
Up to 12 months after the start of ovarian stimulation
|
|
Clinical pregnancy (exploratory)
Ramy czasowe: At 7 weeks of gestation (approximately 5 weeks after the first embryo transfer)
|
Presence of an intrauterine gestational sac on ultrasound after the first fresh or frozen embryo transfer from the index cycle, recorded per initiated index cycle and per transfer. Exploratory only; the study is not powered for this outcome. Reported descriptively. |
At 7 weeks of gestation (approximately 5 weeks after the first embryo transfer)
|
Współpracownicy i badacze
Sponsor
Sponsor
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Szacowany)
Rozpoczęcie studiów
Zakończenie podstawowe (Szacowany)
Zakończenie podstawowe
Ukończenie studiów (Szacowany)
Ukończenie studiów
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Pierwszy wysłany
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia wysłana aktualizacja
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
- Choroby układu moczowo-płciowego
- Choroby narządów płciowych
- Choroby układu moczowo-płciowego kobiet
- Choroby układu moczowo-płciowego kobiet i powikłania ciąży
- Choroby narządów płciowych, kobiety
- Bezpłodność
- Bezpłodność, kobieta
- Hormony
- Hormony, substytuty hormonów i antagoniści hormonów
- Hormony peptydowe
- Peptydy
- Aminokwasy, peptydy i białka
- Hormony przysadki
- Gonadotropiny
- Hormony przysadki, przednie
- Gonadotropiny, przysadki
- Hormon folikulotropowy
Inne numery identyfikacyjne badania
Inne numery identyfikacyjne badania
- OPTIMAL-DOSE-OBS-2026-001
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .